Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Trials as Topic | 6 | 2014 | 460 | 1.120 |
Why?
|
| Drug Industry | 2 | 2014 | 42 | 0.660 |
Why?
|
| Data Interpretation, Statistical | 5 | 2012 | 194 | 0.570 |
Why?
|
| Dideoxynucleosides | 4 | 2010 | 9 | 0.510 |
Why?
|
| Anti-HIV Agents | 4 | 2012 | 156 | 0.480 |
Why?
|
| Information Dissemination | 1 | 2014 | 118 | 0.390 |
Why?
|
| Postoperative Care | 1 | 2013 | 124 | 0.380 |
Why?
|
| Patient Dropouts | 1 | 2012 | 49 | 0.370 |
Why?
|
| Preoperative Care | 1 | 2013 | 199 | 0.360 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 142 | 0.360 |
Why?
|
| HLA-B Antigens | 2 | 2008 | 13 | 0.350 |
Why?
|
| Recovery of Function | 1 | 2013 | 286 | 0.350 |
Why?
|
| Drug Hypersensitivity | 2 | 2008 | 28 | 0.340 |
Why?
|
| HIV Infections | 5 | 2012 | 976 | 0.330 |
Why?
|
| Aging | 1 | 2013 | 754 | 0.260 |
Why?
|
| Anniversaries and Special Events | 1 | 2007 | 15 | 0.260 |
Why?
|
| Societies, Scientific | 1 | 2007 | 36 | 0.260 |
Why?
|
| Genital Neoplasms, Female | 1 | 2005 | 18 | 0.230 |
Why?
|
| Research Design | 3 | 2012 | 583 | 0.190 |
Why?
|
| Sample Size | 2 | 2012 | 66 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2007 | 235 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2007 | 146 | 0.110 |
Why?
|
| Online Systems | 1 | 2014 | 20 | 0.110 |
Why?
|
| Humans | 14 | 2014 | 64272 | 0.110 |
Why?
|
| Access to Information | 1 | 2014 | 30 | 0.100 |
Why?
|
| Confidentiality | 1 | 2014 | 57 | 0.100 |
Why?
|
| Research Personnel | 1 | 2014 | 94 | 0.100 |
Why?
|
| Patient Positioning | 1 | 2013 | 50 | 0.100 |
Why?
|
| Delirium | 1 | 2013 | 55 | 0.090 |
Why?
|
| Myocardial Infarction | 2 | 2009 | 915 | 0.090 |
Why?
|
| Wound Healing | 1 | 2013 | 192 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 147 | 0.090 |
Why?
|
| Government Agencies | 1 | 2011 | 10 | 0.090 |
Why?
|
| Drug and Narcotic Control | 1 | 2011 | 28 | 0.080 |
Why?
|
| Lamivudine | 1 | 2010 | 7 | 0.080 |
Why?
|
| Pain Management | 1 | 2013 | 169 | 0.080 |
Why?
|
| Organophosphonates | 1 | 2010 | 22 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 226 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2010 | 43 | 0.080 |
Why?
|
| Adenine | 1 | 2010 | 50 | 0.080 |
Why?
|
| Bone Density | 1 | 2010 | 136 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2012 | 362 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2013 | 507 | 0.080 |
Why?
|
| Expert Testimony | 1 | 2008 | 27 | 0.070 |
Why?
|
| Drug Approval | 1 | 2008 | 27 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2009 | 167 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2009 | 147 | 0.070 |
Why?
|
| Patch Tests | 1 | 2008 | 11 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 24 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2008 | 28 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 173 | 0.070 |
Why?
|
| Thrombolytic Therapy | 1 | 2009 | 193 | 0.070 |
Why?
|
| Risk Factors | 3 | 2013 | 5341 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2009 | 272 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2008 | 140 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2009 | 192 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2007 | 176 | 0.060 |
Why?
|
| Papillomavirus Vaccines | 1 | 2007 | 70 | 0.060 |
Why?
|
| Pelvic Exenteration | 1 | 2005 | 1 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2005 | 11 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2005 | 42 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 41 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 46 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 93 | 0.060 |
Why?
|
| Aged | 5 | 2013 | 14663 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 132 | 0.060 |
Why?
|
| Hysterectomy | 1 | 2005 | 69 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2005 | 64 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 279 | 0.050 |
Why?
|
| Female | 7 | 2013 | 33383 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 375 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2007 | 175 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 155 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 529 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1164 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2009 | 2048 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2008 | 3318 | 0.040 |
Why?
|
| Young Adult | 3 | 2010 | 4782 | 0.030 |
Why?
|
| Adolescent | 3 | 2010 | 6306 | 0.030 |
Why?
|
| Adult | 4 | 2010 | 17136 | 0.020 |
Why?
|
| Middle Aged | 4 | 2010 | 17923 | 0.020 |
Why?
|
| European Union | 1 | 2011 | 11 | 0.020 |
Why?
|
| Emtricitabine | 1 | 2010 | 8 | 0.020 |
Why?
|
| Tenofovir | 1 | 2010 | 10 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 76 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 168 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 197 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2010 | 140 | 0.020 |
Why?
|
| Coronary Restenosis | 1 | 2009 | 20 | 0.020 |
Why?
|
| United Kingdom | 1 | 2009 | 81 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 48 | 0.020 |
Why?
|
| Male | 4 | 2010 | 30322 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2009 | 209 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 130 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 859 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2007 | 59 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2007 | 137 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 554 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2007 | 98 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 744 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 668 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 320 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2007 | 291 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 529 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 2482 | 0.010 |
Why?
|
| HIV-1 | 1 | 2008 | 725 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 3725 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 5528 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 5696 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 6741 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 20955 | 0.000 |
Why?
|